PRESS RELEASE: REGULATED INFORMATION
17 December 2020, 07:00 CET
DISCLOSURE OF OUTSTANDING VOTING SECURITIES
Mechelen, Belgium, 17 December 2020 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that 1,163,575 new shares were issued on 14 December 2020 as a result of the conversion of 150 4% Senior Unsecured Convertible Bonds due 2024, as previously announced on 7 December 2020.
In view hereof, and in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous provisions (the ‘Belgian Act’), the outstanding share capital and outstanding voting securities of the Company can be summarised as follows:
Total outstanding share capital: EUR 575,456.63;
Total outstanding voting securities: 57,545,663;
Total outstanding voting rights: 57,545,663;
Shares that can still be issued: 14,316,006 shares (each share entailing one voting right), of which:
294,375 shares can be issued upon the exercise of 294,375 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the ‘2013 Plan’ for employees, consultants and management members, entitling the holders thereof to acquire one new share per option;
210,052 shares can be issued upon the exercise of 210,052 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the ‘2015 Plan’ for employees, consultants, management members and directors, entitling the holders thereof to acquire one new share per option;
1,212,365 shares can be issued upon the exercise of 1,212,365 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the ‘2017 Plan’ for the CEO, entitling the holder thereof to acquire one new share per option;
571,560 shares can be issued upon the exercise of 571,560 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the ‘2018 Plan’ for (mainly) certain selected employees of the Company and its subsidiaries, as well as for consultants of the Company and its subsidiaries, independent directors of the Company and directors of the Company's subsidiaries, entitling the holders thereof to acquire one new share per option;
695,476 shares can be issued upon the exercise of 695,476 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2020 Plan' for members of the personnel of the Company and/or its subsidiaries, entitling the holders thereof to acquire one new share per option;
860,000 shares can be issued upon the exercise of 860,000 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2020B Plan' for members of the executive management of the Company, entitling the holders thereof to acquire one new share per option; and
10,472,178 shares can be issued upon the conversion of all 1,350 outstanding 4.00 per cent senior unsecured convertible bonds due 2024 (the ‘2024 Convertible Bonds’) at their current conversion price of EUR 12.8913 per share, provided, however, that the conversion price of the 2024 Convertible Bonds may be subject to adjustment in accordance with the terms and conditions of the 2024 Convertible Bonds.
Pursuant to the Belgian Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.
----- END ----
Head of Corporate Communications & Investor Relations Biocartis
tel +32 15 631 729
mobile +32 471 53 60 64
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.
Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.